Moderna has said that it is gearing up to halve the dose of its Covid-19 vaccine so that it can also be used to combat variants and inoculate children, Reuters reports.
It has agreed to a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen, Netherlands, would have the capacity to make ingredients for up to 300 million doses annually at 50 microgrammes per dose.
"We're assuming that as of 2022, we are going to have a mix of dose levels on the market," a spokeswoman for Moderna said, following the announcement of Lonza's new production.
Read more at Reuters here.
